Clinical improvement in a patient with neuromyelitis optica following therapy with the anti-IL-6 receptor monoclonal antibody tocilizumab (Q24598109)

2

0 references

Takako Matsuoka

3

0 references

Masakazu Nakamura

4

0 references

Sachiko Miyake

5

0 references

Takashi Yamamura

IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel

6

0 references

language of work or name

English

0 references

publication date

July 2013

0 references

published in

Modern Rheumatology

0 references

volume

23

0 references

issue

4

0 references

page(s)

827-31

0 references

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3713263

Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)

24 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3713263

A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis

24 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3713263

Therapeutic targeting of the interleukin-6 receptor.

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3713263

Interleukin 6 signaling promotes anti-aquaporin 4 autoantibody production from plasmablasts in neuromyelitis optica.

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3713263

Review: Treatment of neuromyelitis optica: Current debate

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3713263

IFNβ-1b may severely exacerbate Japanese optic-spinal MS in neuromyelitis optica spectrum

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3713263

Intra-cerebral injection of neuromyelitis optica immunoglobulin G and human complement produces neuromyelitis optica lesions in mice.

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3713263

Neuromyelitis optica: pathogenicity of patient immunoglobulin in vivo.

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3713263

Revised diagnostic criteria for neuromyelitis optica

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3713263

A role for humoral mechanisms in the pathogenesis of Devic's neuromyelitis optica

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3713263

Failure of natalizumab to prevent relapses in neuromyelitis optica

27 September 2017

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS10165-012-0715-9

Development of extensive brain lesions following fingolimod (FTY720) treatment in a patient with neuromyelitis optica spectrum disorder

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS10165-012-0715-9

An open label study of the effects of rituximab in neuromyelitis optica

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS10165-012-0715-9

Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22782533

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Induction of proliferation and Ig production in human B leukemic cells by anti-immunoglobulins and T cell factors

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22782533